Cediranib maleate
CAS No. 857036-77-2
Cediranib maleate ( AZD-2171 maleate | AZD 2171 maleate )
产品货号. M16216 CAS No. 857036-77-2
一种高效、口服生物可利用的泛 VEGFR 抑制剂,对 VEGFR1、2、3 的 IC50 分别为 1、5、3 nM。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥1568 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ¥1824 | 有现货 |
|
生物学信息
-
产品名称Cediranib maleate
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述一种高效、口服生物可利用的泛 VEGFR 抑制剂,对 VEGFR1、2、3 的 IC50 分别为 1、5、3 nM。
-
产品描述A highly potent, orally bioavailable, pan-VEGFR inibitor with IC50 of 1, 5, 3 nM for VEGFR1, 2, 3, respectively; also inhibits c-Kit and PDGFRβ with IC50 of 2 and 5 nM, >36-fold selectivity over PDGFR-α, >1000-fold over Flt-3 and EGFR; inhibits VEGF-stimulated proliferation and KDR phosphorylation with IC50 of 0.4 and 0.5 nM in human umbilical vein endothelial cells; inhibits angiogenesis, neovascular survival and tumor growth in vivo. Ovarian Cancer Phase 3 Clinical.
-
体外实验In human umbilical vein endothelial cells, Cediranib inhibits VEGF-stimulated proliferation and KDR phosphorylation with IC50 values of 0.4 and 0.5 nM, respectively. In a fibroblast/endothelial cell coculture model of vessel sprouting, Cediranib also reduces vessel area, length, and branching at subnanomolar concentrations.
-
体内实验Once-daily oral administration of Cediranib ablates experimental (VEGF-induced) angiogenesis and inhibits endochondral ossification in bone or corpora luteal development in ovary; physiologic processes that are highly dependent upon neovascularization. The growth of established human tumor xenografts (colon, lung, prostate, breast, and ovary) in athymic mice is inhibited dose-dependently by Cediranib, with chronic administration of 1.5 mg per kg per day producing statistically significant inhibition in all models. A histologic analysis of Calu-6 lung tumors treated with Cediranib reveals a reduction in microvessel density within 52 hours that becomes progressively greater with the duration of treatment. These changes are indicative of vascular regression within tumors.
-
同义词AZD-2171 maleate | AZD 2171 maleate
-
通路Angiogenesis
-
靶点VEGFR
-
受体VEGFR
-
研究领域Cancer
-
适应症Ovarian Cancer
化学信息
-
CAS Number857036-77-2
-
分子量566.5775
-
分子式C29H31FN4O7
-
纯度>98% (HPLC)
-
溶解度DMSO: ≥ 45 mg/mL
-
SMILESCC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5.C(=CC(=O)O)C(=O)O
-
化学全称Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-, (2Z)-2-butenedioate (1:1)
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Wedge SR, et al. Cancer Res. 2005 May 15;65(10):4389-400.
2. Denduluri N, et al. Clin Breast Cancer. 2005 Dec;6(5):460-3.
3. Batchelor TT, et al. Cancer Cell. 2007 Jan;11(1):83-95.
4. Cao C, et al. Cancer Res. 2006 Dec 1;66(23):11409-15.
产品手册
关联产品
-
R1530
R1530 是一种多激酶抑制剂,具有抗肿瘤和抗血管生成活性。
-
TG 100801
TG 100801 是TG 100572的前体,通过去酯化产生TG 100572,开可用于黄斑变性的研究。TG 100572 是多靶点激酶抑制剂,抑制受体酪氨酸激酶 (receptor tyrosine kinases) 和Src激酶 (Src kinases); 对VEGFR1,VEGFR2,FGFR1,FGFR2,PDGFRβ,Fgr,Fyn,Hck,Lck,Lyn,Src,Yes 的 IC50 值分别为2,7,2,16,13,5,0.5,6,0.1,0.4,1,0.2。
-
TAS-115
TAS-115 是一种有效的 VEGFR 和肝细胞生长因子受体 (c-Met/HGFR) 靶向激酶抑制剂(rVEGFR2 和 rMET 的 IC50 分别为 30 和 32 nM)。
021-51111890
购物车()
sales@molnova.cn

